2022
Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis
Kanbay M, Yildiz AB, Siriopol D, Vehbi S, Hasbal NB, Kesgin YE, Celayir M, Selcukbiricik F, Covic A, Perazella MA. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. International Urology And Nephrology 2022, 55: 1025-1032. PMID: 36282399, DOI: 10.1007/s11255-022-03395-y.Peer-Reviewed Original ResearchConceptsAcute kidney injuryImmune checkpoint inhibitorsSolid organ malignanciesCheckpoint inhibitorsKidney injuryOrgan malignanciesNephrotoxic agentsSingle-center retrospective cohort studyType of ICIBaseline serum creatinine levelAcute interstitial nephritisLocation of malignancyRetrospective cohort studySerum creatinine levelsKidney function recoveryRenal replacement therapyUrinary tract obstructionRisk of mortalityICPI treatmentRenal prognosisTract obstructionCohort studyCreatinine levelsFive patientsInterstitial nephritis
2021
Immunotherapy-Related Acute Kidney Injury
Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-Related Acute Kidney Injury. Advances In Kidney Disease And Health 2021, 28: 429-437.e1. PMID: 35190109, DOI: 10.1053/j.ackd.2021.07.006.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyEffective immune checkpoint inhibitorsAcute kidney injuryImmune checkpoint inhibitorsHigh-dose interleukinNumerous clinical trialsT-cell therapyField of oncologyCheckpoint inhibitorsKidney injuryGeneration immunotherapiesClinical trialsClinical practiceImmunotherapyImmune systemAdverse effectsNephrotoxicityInterleukinPathophysiologyInjuryTherapyCancerOncologyTrials
2020
Onconephrology: The intersections between the kidney and cancer
Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA A Cancer Journal For Clinicians 2020, 71: 47-77. PMID: 32853404, DOI: 10.3322/caac.21636.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseDrug-induced nephrotoxicityKidney diseaseElectrolyte disordersAcute kidney injuryStem cell transplantationParaneoplastic glomerulonephritisKidney injuryCell transplantationTherapeutic regimensCollaborative careCancerDiseasePatientsOnconephrologyNew subspecialtySpecific training programsNephrotoxicityDisordersTraining programGlomerulonephritisRegimensNephrologistsTransplantationOncologistsHow to determine kidney function in cancer patients?
Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients? European Journal Of Cancer 2020, 132: 141-149. PMID: 32361629, DOI: 10.1016/j.ejca.2020.03.026.Peer-Reviewed Original ResearchConceptsGlomerular filtration rateKidney functionCancer patientsDifferent glomerular filtration ratesAppropriate dose adjustmentCKD-EPI formulaSerum creatinine concentrationNarrow therapeutic indexDose adjustmentFiltration rateClinical trialsCreatinine concentrationTherapeutic indexAnti-cancer drugsPatientsToxic drugsDrugsBody surfaceTrials
2019
Improving Cancer Care for Patients With Chronic Kidney Disease.
Sprangers B, Jhaveri KD, Perazella MA. Improving Cancer Care for Patients With Chronic Kidney Disease. Journal Of Clinical Oncology 2019, 38: 188-192. PMID: 31800342, DOI: 10.1200/jco.19.02138.Peer-Reviewed Original Research
2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosis